1 319

Cited 5 times in

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane

DC FieldValueLanguage
dc.contributor.author남정모-
dc.contributor.author라선영-
dc.contributor.author안중배-
dc.contributor.author양우익-
dc.contributor.author임승택-
dc.contributor.author전홍재-
dc.contributor.author정현철-
dc.contributor.author정희철-
dc.contributor.author홍민희-
dc.contributor.author강버들-
dc.contributor.author박지수-
dc.date.accessioned2015-01-06T17:21:02Z-
dc.date.available2015-01-06T17:21:02Z-
dc.date.issued2014-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99814-
dc.description.abstractPURPOSE: We conducted a phase II study evaluating safety and efficacy of combination gemcitabine and capecitabine therapy for metastatic breast cancer patients following anthracycline and taxane treatment in Korea. METHODS: This was a single-arm, non-randomized phase II study. Patients received 1,000 mg/m(2) gemcitabine intravenously over 30 min on days 1 and 8, and 1,250 mg/m(2) capecitabine orally twice daily on days 1-14 until disease progression or intolerable toxicity occurred. This regimen was repeated every 3 weeks. The primary outcome assessed was overall response rate [ORR, complete response (CR) + partial response (PR) as the best response], and secondary outcomes were progression-free survival (PFS), overall survival (OS), disease control rate (DCR) [maintenance of CR + PR + stable disease (SD) for at least 3 months], drug toxicity, and predictive factors for response to this regimen. RESULTS: Of 41 patients, the ORR was 39.0% (CR 0%; PR 39.0%), and DCR was 78.0% using this chemotherapy. DCR for 6 and 12 months was 68.3 and 26.8%, respectively. Median PFS was 10.0 months [95% confidence interval (CI) 7.8-12.1], and median OS was 25.1 months (95% CI 18.2-32.1). Prominent toxicities were neutropenia and hand-foot syndrome. Most adverse events were well known, relatively moderate, and reversible. Taxane sensitivity [odds ratio (OR) 0.169; 95% CI 0.034-0.826; P = 0.028] and hepatic metastasis (OR 0.097; 95% CI 0.017-0.559; P = 0.009) were significantly predictive of response to gemcitabine and capecitabine combination. CONCLUSIONS: This study showed reproducible anticancer activity and tolerable toxicity of gemcitabine and capecitabine combination therapy in recurrent or metastatic Korean breast cancer patients previously treated with anthracycline and taxane.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfCancer Chemotherapy and Pharmacology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnthracyclines*/administration & dosage-
dc.subject.MESHAnthracyclines*/adverse effects-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHAntineoplastic Agents/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHBreast Neoplasms*/drug therapy-
dc.subject.MESHBreast Neoplasms*/mortality-
dc.subject.MESHBreast Neoplasms*/pathology-
dc.subject.MESHBridged-Ring Compounds*/administration & dosage-
dc.subject.MESHBridged-Ring Compounds*/adverse effects-
dc.subject.MESHCapecitabine-
dc.subject.MESHDeoxycytidine/administration & dosage-
dc.subject.MESHDeoxycytidine/adverse effects-
dc.subject.MESHDeoxycytidine/analogs & derivatives*-
dc.subject.MESHDisease Progression-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Screening Assays, Antitumor-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHFluorouracil/adverse effects-
dc.subject.MESHFluorouracil/analogs & derivatives*-
dc.subject.MESHHand-Foot Syndrome*/etiology-
dc.subject.MESHHand-Foot Syndrome*/physiopathology-
dc.subject.MESHHand-Foot Syndrome*/prevention & control-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHNeutropenia*/chemically induced-
dc.subject.MESHNeutropenia*/physiopathology-
dc.subject.MESHNeutropenia*/prevention & control-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSeverity of Illness Index-
dc.subject.MESHTaxoids*/administration & dosage-
dc.subject.MESHTaxoids*/adverse effects-
dc.subject.MESHTreatment Outcome-
dc.titlePhase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorJi Soo Park-
dc.contributor.googleauthorHei-Cheul Jeung-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorJoong Bae Ahn-
dc.contributor.googleauthorBeodeul Kang-
dc.contributor.googleauthorHong Jae Chon-
dc.contributor.googleauthorMin Hee Hong-
dc.contributor.googleauthorSeungtaek Lim-
dc.contributor.googleauthorWoo Ick Yang-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorHyun Cheol Chung-
dc.identifier.doi10.1007/s00280-014-2551-4-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01264-
dc.contributor.localIdA02262-
dc.contributor.localIdA02300-
dc.contributor.localIdA03380-
dc.contributor.localIdA03565-
dc.contributor.localIdA03773-
dc.contributor.localIdA04393-
dc.contributor.localIdA00029-
dc.contributor.localIdA03794-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ00437-
dc.identifier.pmid25107569-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00280-014-2551-4-
dc.subject.keywordBreast cancer-
dc.subject.keywordMetastatic-
dc.subject.keywordRecurrent-
dc.subject.keywordGemcitabine-
dc.subject.keywordCapecitabine-
dc.subject.keywordChemotherapy-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.alternativeNameYang, Woo Ick-
dc.contributor.alternativeNameLim, Seung Taek-
dc.contributor.alternativeNameChon, Hong Jae-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameJeung, Hei Cheul-
dc.contributor.alternativeNameHong, Min Hee-
dc.contributor.alternativeNameKang, Beo Deul-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.contributor.affiliatedAuthorYang, Woo Ick-
dc.contributor.affiliatedAuthorLim, Seung Taek-
dc.contributor.affiliatedAuthorChon, Hong Jae-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHong, Min Hee-
dc.contributor.affiliatedAuthorKang, Beo Deul-
dc.contributor.affiliatedAuthorJeung, Hei Cheul-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.rights.accessRightsfree-
dc.citation.volume74-
dc.citation.number4-
dc.citation.startPage799-
dc.citation.endPage808-
dc.identifier.bibliographicCitationCancer Chemotherapy and Pharmacology, Vol.74(4) : 799-808, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.